If you want a Stock Review on PBYI, REGN, SRPT, or SGEN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Wednesday, September 13, 2017, the NASDAQ Composite ended the trading session at 6,460.19, up 0.09%; the Dow Jones Industrial Average edged 0.18% higher, to finish at 22,158.18; and the S&P 500 closed at 2,498.37, slightly advancing 0.08%. US markets saw four out of nine sectors finishing the day in red, 3 in green, and 2 in neutral territory. This Thursday, DailyStockTracker.com has initiated reports coverage on the following Biotechnology equities: Puma Biotechnology Inc. (NASDAQ: PBYI), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), and Seattle Genetics Inc. (NASDAQ: SGEN). Take a look at the free research reports issued today on DailyStockTracker.com for these stocks by signing up at:

Puma Biotech 

Los Angeles, California headquartered Puma Biotechnology Inc.’s stock finished Wednesday’s session 1.12% higher at $103.90 with a total trading volume of 418,766 shares. The Company’s shares have advanced 29.79% in the last month, 30.61% in the previous three months, 69.60% over the past twelve months, and 238.44% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 16.39% and 85.90%, respectively. Additionally, shares of Puma Biotechnology, which focuses on the development and commercialization of products to improve cancer care, have a Relative Strength Index (RSI) of 67.22.

On September 11th, 2017, research firm Credit Suisse reiterated its ‘Outperform’ rating on the Company’s stock with an increase of the target price from $118 a share to $136 a share. Sign up and read the free research report on PBYI at:

Regeneron Pharma 

On Wednesday, shares in Tarrytown, New York headquartered Regeneron Pharmaceuticals Inc. recorded a trading volume of 1.06 million shares, which was above its three months average of 845.89 thousand shares. The stock ended the session 1.52% lower at $437.74. The Company’s shares have advanced 11.96% over the last twelve months and 19.25% on an YTD basis. The stock is trading above its 200-day moving average by 3.88%. Moreover, shares of Regeneron Pharma, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide, have an RSI of 31.72.

On September 06th, 2017, research firm Raymond James resumed its ‘Outperform’ rating on the Company’s stock, with a target price of $566 per share. The complimentary research report on REGN can be downloaded at:

Sarepta Therapeutics 

Cambridge, Massachusetts headquartered Sarepta Therapeutics Inc.’s shares closed the day 1.56% higher at $44.79. The stock recorded a trading volume of 1.54 million shares. The Company’s shares have gained 18.43% in the last month, 35.15% over the previous three months, 74.96% over the last twelve months, and 63.29% since the start of the year. The stock is trading above its 50-day and 200-day moving averages by 16.55% and 33.99%, respectively. Additionally, shares of Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, have an RSI of 64.69. Register for free on DailyStockTracker.com and access the latest report on SRPT at:

Seattle Genetics 

Shares in Bothell, Washington headquartered Seattle Genetics Inc. finished 0.47% higher at $53.40. The stock recorded a trading volume of 863,828 shares. The Company’s shares have advanced 16.29% in the last month. The stock is trading above its 50-day moving average by 5.31%. Furthermore, shares of Seattle Genetics, which develops and commercializes targeted therapies to treat cancer worldwide, have an RSI of 61.91. Get free access to your research report on SGEN at:

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected] . Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit:

For any questions, inquiries, or comments reach out to us directly. If youre a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com

Powered by WPeMatico

Previous articleRobbie F. Thomas Recognized as a Professional of the Year by Strathmore’s Who’s Who Worldwide Publication
Next article7Days Inn et OGC Nice coopèrent de manière stratégique pour élargir leur marché à l’international
Arul Is a researcher and law student at Anna University (Chennai). He has worked as the Director of the Graduate Lawyering Program.